Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% Higher – Here’s Why

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) were up 6.6% during trading on Monday . The stock traded as high as $19.21 and last traded at $19.13. Approximately 341,212 shares were traded during mid-day trading, a decline of 51% from the average session volume of 700,079 shares. The stock had previously closed at $17.94.

Analyst Ratings Changes

KLRA has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price target on the stock. Leerink Partners initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price objective for the company. William Blair began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating on the stock. Evercore assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating on the stock. Finally, Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $42.75.

Kailera Therapeutics Price Performance

The firm has a market cap of $2.48 billion and a price-to-earnings ratio of -0.01. The stock has a 50-day moving average of $19.43.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). Sell-side analysts anticipate that Kailera Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.